Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell. The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce longer remissions. The study involves NSCLC tumors which are driven by a mutation in the gene EGFR...

Older, current and former heavy smokers should receive annual, low-dose CT screening, according to revised guidelines published in the Journal of the American Medical Association on Sunday. The revised guidelines follow, and in the JAMA paper are accompanied by, a systematic review of evidence on the ...

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas - the most common type of non-small cell lung cancer - and have developed drugs that ...

The most recent research released in June's Journal of Thoracic Oncology says video assisted thoracic surgery (VATS) is a valuable tool in managing lesions detected in a lung cancer screening program. The primary objective of lung cancer screening with low dose computer tomography (CT) is to detect lung cancer at ...

The most recent research released in June's Journal of Thoracic Oncology says molecular biomarkers in the tissue and fluid lining the lungs might be an additional predictive technique for lung cancer screening. Since the National Lung Screening Trial found that 96.4 percent of the positive CT screening results were false ...

The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer. The study, published in the June 2012 issue of the International Association for ...

Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response ...

Lung cancer is the leading cause of cancer death throughout the world. Standard treatment methods do not usually result in long-term recovery. In addition to the proliferation of the tumour cells, the growth of blood vessels controls tumors development. The blood vessel growth is controlled by several signalling molecules. Scientists ...